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Abstract
Mutations in SCO2 are among the most common causes of COX deficiency, resulting in reduced mitochondrial oxidative ATP production capac-
ity, often leading to hypertrophic cardiomyopathy (HCM). To date, none of the recent pertaining reports provide deep understanding of the
SCO2 disease pathophysiology. To investigate the cardiac pathology of the disease, we were the first to generate induced pluripotent stem cell
(iPSC)-derived cardiomyocytes (iPSC-CMs) from SCO2-mutated patients. For iPSC generation, we reprogrammed skin fibroblasts from two
SCO2 patients and healthy controls. The first patient was a compound heterozygote to the common E140K mutation, and the second was homo-
zygote for the less common G193S mutation. iPSC were differentiated into cardiomyocytes through embryoid body (EB) formation. To test the
hypothesis that the SCO2 mutation is associated with mitochondrial abnormalities, and intracellular Ca2+-overload resulting in functional
derangements and arrhythmias, we investigated in SCO2-mutated iPSC-CMs (compared to control cardiomyocytes): (i) the ultrastructural
changes; (ii) the inotropic responsiveness to b-adrenergic stimulation, increased [Ca2+]o and angiotensin-II (AT-II); and (iii) the Beat Rate Vari-
ability (BRV) characteristics. In support of the hypothesis, we found in the mutated iPSC-CMs major ultrastructural abnormalities and markedly
attenuated response to the inotropic interventions and caffeine, as well as delayed afterdepolarizations (DADs) and increased BRV, suggesting
impaired SR Ca2+ handling due to attenuated SERCA activity caused by ATP shortage. Our novel results show that iPSC-CMs are useful for
investigating the pathophysiological mechanisms underlying the SCO2 mutation syndrome.
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Introduction
Derangements in the mitochondrial respiratory chain and specifi-
cally in cytochrome c oxidase (COX) are associated with deleteri-
ous effects in organs with high energy demands, such as the
heart. Consequently, cardiac pathologies are a prevalent outcome
of mitochondrial-related disorders [1]. The human SCO2 gene
encodes a 266-amino-acid metallochaperone that participates in
copper delivery to COX [2], and thus mutations in SCO2 are
among the most common causes of COX deficiency [3]. These
disorders are characterized by encephalopathy and HCM, collec-
tively leading to death in infancy or early childhood [4]. Based on
the COX deficiency caused by SCO2 mutations (resulting in ATP
shortage), we hypothesized that the SCO2 mutation is associated
with mitochondrial abnormalities, and intracellular Ca2+-overload
resulting in functional derangements and arrhythmias. To test this
hypothesis, we investigated in SCO2-mutated iPSC-CMs generated
from two babies (who died at 3–4 months) carrying different
SCO2 mutations: (i) the ultrastructural changes; (ii) the inotropic
responsiveness to b-adrenergic stimulation, increased [Ca2+]o and
AT-II; and (iii) the Beat Rate Variability (BRV) characteristics. In
support of our hypothesis, the diseased cardiomyocytes demon-
strated abnormal mitochondrial ultrastructure, functional derange-
ments including arrhythmias, suggesting disturbed intracellular
Ca2+ homoeostasis, likely due to ATP deficiency.
Materials and methods
iPSC generation and characterization
Dermal biopsies were obtained from two SCO2-mutated patients (ba-
bies) and two healthy donors (adults): (i) an Israeli male baby treated
at the Rambam Health Care Campus in Haifa; (ii) an Estonian male baby
treated at Tartu University Hospital in Estonia; (iii) a healthy adult Israeli
female; (iv) a healthy adult Israeli male. Additionally, hair follicles were
collected from a healthy adult Israeli female. iPSC were generated from
the donors dermal fibroblasts (clones 5.2, 17.2, 24.5 and 27.10) or hair
keratinocytes (clone N3) previously described [5]. Following reprogram-
ming, we used iPSC clones 17.2 and 27.10 generated from the Israeli
and Estonian babies, accordingly. As control, we used clone 24.5 gener-
ated from a healthy 42-year-old female [5, 6]. Additional control clones
(5.2 and N3) were generated from healthy 25- and 23-year-old male
and female, respectively. Clone FSE-5 m was generated from an infant
male and was used for b-adrenergic responsiveness experiments.
Unless stated otherwise, the control clone referred to in the article and
Supporting information is 24.5 (HDF). Functional iPSC-CMs were gener-
ated as previously described [7–9]. Karyotyping, genotyping and
pluripotency assay using teratoma formation assay are detailed in the
Supporting information.
Immunofluorescence staining
See details in the Supporting information.
Measurements of intracellular [Ca2+]i
transients, contractions, extracellular
electrograms, transmembrane action potentials
and BRV
All methods and protocols are detailed in the Supporting information. In
brief, [Ca2+]i transients and contractions were measured from iPSC-CMs
composing embryoid bodies (EBs), using the IonOptix Calcium and
Contractility system (Westwood, MA, USA), as previously described [5,
10]. Transmembrane action potentials and extracellular electrograms
were recorded by means of the whole cell patch clamp and microelec-
trode array (MEA), respectively [11, 12].
Transmission electron microscopy of the skeletal
muscle biopsy and iPSC-CMs
The Israeli patient underwent a muscle (gastrocnemius) biopsy as part
of the studies performed in patients with suspected mitochondrial disor-
der (see Supporting information for details). Transmission electron
microscopy (TEM) analysis was performed on 15-, 30- and 45-day-old
(post-plating) EBs from SCO2G193S clone 17.2, SCO2E140K clone 27.10
and control clone 24.5 as previously reported [13]. See details in the
Supporting information.
Statistical analysis
Results are presented as mean  S.E.M. See details in the Supporting
information.
Results
The SCO2-mutated patients
The Israeli patient was homozygote for a less common c.577G>A
mutation in the SCO2 gene, termed SCO2G193S. This patient, hospi-
talized at the age of 3 months, had congenital stridor, encephalopa-
thy, skeletal myopathy and lactic acidosis. Echocardiography and
electrocardiography (ECG) performed at 4 months demonstrated
major left ventricle hypertrophy (Fig. S1A and B). Electron micro-
scopy of a muscle biopsy demonstrated glycogen accumulation and
abnormal mitochondria (Fig. S1C and D). Enzyme assay indicated
COX deficiency (1.2 K/mg) compared to normal values
(16.81  6.51 K/mg). The patient died at the age of 4 months due
to cardiorespiratory failure. The Estonian patient had a compound
heterozygote mutation c.418G>A in exon 2, termed SCO2E140K and a
heterozygote c.17INS19 bp mutation in the coding region. As previ-
ously described, the patient was diagnosed with fatal infantile car-
dioencephalomyopathy and died at the age of 13 weeks due to
respiratory insufficiency. Abnormalities in mitochondria size and
structure and low COX activity levels were found in fibroblasts and
muscle biopsies [14].
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Fig. 1 TEM images of control and SCO2-mutated iPSC-CMs. (A) Normal ultrastructure of 30-day-old control iPSC-CMs with organized myofibrils
(mf), grouped normal mitochondria (nm) and glycogen masses (gly). NC-nucleus. (B) Higher magnification of the square marked area in (A) shows
normal mitochondria (nm) from control iPSC-CMs, containing parallel cristae (arrowheads). (C) 30-day-old SCO2G193S iPSC-CMs contain higher
glycogen (gly) content, lipid droplets (L), poor organized myofibrils (mf) and oversized mitochondria (M). The intercellular space is enlarged com-
pared with control. NC-nucleus. (D) Enlarged mitochondrion (M) from 30-day-old SCO2G193S iPSC-CMs (square marked area in C) shows increased
number of disarrayed cristae, vacuolated cristae (red arrow) and glycogen inclusions (gly). A normal mitochondrion (nm) is visible nearby. (E) 30-
day-old SCO2E140K cardiomyocytes show organized myofibrils (mf), large masses of glycogen (gly), lipid droplets (L) and clusters of mitochondria
(nm). NC-nucleus. (F) Higher magnification of the square marked area in E shows normal structured mitochondria (nm) and slightly enlarged,
doughnut-shaped mitochondria (M). gly: glycogen.
ª 2017 The Authors.
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iPSC generation, characterization and
differentiation into cardiomyocytes
The SCO2 iPSC clones from both patients expressed the pluripotent
markers SSEA4, Oct4, TRA1-60, Nanog, TRA1-81 and Sox2, had nor-
mal karyotype, and demonstrated pluripotency by in vivo differentiation
into derivatives of all three germ layers (Figs S2–4). In addition, we con-
firmed the homozygote switch of G to A at nucleotide 577 in the
SCO2G193S gene, the heterozygote switch of G to A at nucleotide 418 in
one allele and the insertion c.17INS19 bp in the second allele of the
SCO2E140K gene (Figs S3 and 4). The healthy control clones 24.5 (HDF),
5.2 (HDF) and N3 (KT) were fully characterized previously (Fig. S7).
Transmission electron microscopy analysis
First, TEM analysis in 30-day-old control (Fig. 1A and B) and
SCO2G193S iPSC-CMs (Fig. 1C and D) showed enlarged mitochondria,
disarrayed mitochondrial cristae, intra-mitochondrial vacuoles, large
masses of glycogen, lipid droplets and doubled nuclei in the mutated
cardiomyocytes. In contrast, SCO2E140K iPSC-CMs displayed only
high quantities of glycogen and lipid droplets with minor mitochon-
drial ultrastructural changes (Fig. 1E and F; Fig. S5). While normal
mitochondria had diameter of 0.30  0.06 lm (n = 50), in
SCO2G193S iPSC-CMs mitochondria were much larger—
0.50  0.37 lm (n = 50, P < 0.001 versus control) (Table S1).
Next, we found that ageing (15, 30 and 45 days) of SCO2G193S iPSC-
CMs was associated with progression of the ultrastructural mitochon-
drial abnormalities compared with mitochondria from control and
SCO2E104K iPSC-CMs. While 15-day-old cardiomyocytes showed mild
mitochondrial abnormalities (Fig. 2D), 30-day-old cardiomyocytes
demonstrated abnormally large mitochondria with few tightly packed
cristae and intra-mitochondrial glycogen accumulation (Fig. 2E).
Accordingly, 45-day-old cardiomyocytes displayed oversized mito-
chondria, with disarrayed and highly increased number of curled cris-
tae (Fig. 2F).
Fig. 2 TEM images showing mitochondria from 15-, 30- and 45-day-old control (A–C), SCO2G193S (D–F) and SCO2E140K (G–I) iPSC-CMs. Normal
mitochondria show few parallel cristae (nm). The mitochondria abnormalities (M) progress with the age of SCO2G193S iPSC-CMs: disarray and
decreased number of mitochondrial cristae (D); few tightly packed cristae and glycogen accumulation inside the mitochondrion (E); mitochondria
are enlarged and contain disarrayed and highly increased number of cristae (F). SCO2E140KiPSC-CMs present mostly mitochondria with normal ultra-
structure (nm) (G-I) and rare doughnut-like mitochondria (M) at 45 days (I), mf: myofibrils; NC: nuclei.
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Functional characteristics and responsiveness to
positive inotropic interventions
The first step in this series of experiments was to determine
whether the mutated cardiomyocytes have different [Ca2+]i tran-
sient and contraction characteristics than control cardiomyocytes.
As seen in Figure S6, all the functional characteristics were similar
in the three experimental groups, suggesting that the mutation did
not affect the basal excitation–contraction coupling machinery.
Next, to test our working hypothesis, we investigated the inotropic
effects of b-adrenergic stimulation (with isoproterenol), increased
[Ca2+]o and AT-II.
b-adrenergic stimulation
A fundamental cardiac feature is b-adrenergic-mediated positive ino-
tropy caused by increased SR Ca2+ release, which relies on the ATP-
dependent SERCA activity [15]. As shown in Figure 3, isoproterenol
caused marked dose-dependent positive inotropic and lusitropic
effects in control iPSC-CMs (n = 18, P < 0.05). Importantly, similar
effects were observed in other control clones including 5.2 (HDF) and
N3 (KT) (Fig. S8). In contrast, SCO2G193S (n = 19) and SCO2E140K
(n = 11) iPSC-CMs were completely unresponsive to isoproterenol
(P < 0.05 compared to control).
Effects of increased [Ca2+]o
To decipher whether the attenuated response to isoproterenol was due
to dysfunctional b-adrenergic cascade or alternatively—impaired
downstream element mediating any positive inotropic intervention, we
investigated the effect of elevating [Ca2+]o; this intervention augments
L-type Ca2+ current (ICa,L), which in turn increases SR Ca
2+ release
thereby increasing contractile force [16]. Indeed, as shown in Fig-
ure 4A–C, in control cardiomyocytes (n = 12), elevating [Ca2+]o
caused positive inotropic and lusitropic effects (P < 0.001), although
the [Ca2+]i transients were affected to a lesser extent than contractions
(Fig. 4D–F). In contrast, in agreement with their depressed response to
isoproterenol, both SCO2G193S and SCO2E140K iPSC-CMs were com-
pletely unresponsive (P < 0.05 versus control) to increased [Ca2+]o.
Effects of AT-II
Based on the above findings, our interim conclusion was that the com-
mon downstream denominator of these positive inotropic interventions
is a defective SR in the mutated iPSC-CMs. To support this notion, we
investigated whether AT-II, also inducing its positive inotropy via SR-
Ca2+ [17], is equally ineffective in the mutated cardiomyocytes. Indeed,
whereas in control iPSC-CMs AT-II caused prominent dose-dependent
positive inotropic and lusitropic effects (n = 17, P < 0.05), SCO2G193S
(n = 13) and SCO2E140K (n = 14) iPSC-CMs were unresponsive
Fig. 3 The effects of isoproterenol on [Ca2+]i transients and contractions in control, SCO2
G193S and SCO2E140K iPSC-CMs. (A–C) [Ca2+]i transients
(R = F340/F380) and contractions (Lamp) from control, SCO2
G193S and SCO2E140K iPSC-CMs, respectively. (D) [Ca2+]i transient amplitude (Ramp); (E)
maximal rate of [Ca2+]i rise (+d[Ca
2+]/dt); (F) maximal rate of [Ca2+]i decay (-d[Ca
2+]/dt); (G) maximal amplitude (Lamp); (H) maximal contraction
rate (+dL/dt); (I) maximal relaxation rate (dL/dt). The effect of isoproterenol on contraction characteristics of SCO2G193S (n = 13), SCO2E140K
(n = 6) and control (n = 8) was expressed as per cent change. The effect of isoproterenol on the [Ca2+]i transients was expressed as the per cent
change in the fluorescence ratio, F340/F380 (n = 6, n = 5 and n = 10, for SCO2
G193S, SCO2E140K and control respectively); Tyr: Tyrode’s solution;
*P < 0.05, **P < 0.001 (versus control).
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
917
J. Cell. Mol. Med. Vol 22, No 2, 2018
(Fig. 4G–L). Hence, except for the maximal rate of [Ca2+]i decay which
was not different between control and SCO2G193S iPSC-CMs (significant
only at 106M, P < 0.001), all control dose-response relations were
significantly (P < 0.05) different from the mutated cardiomyocytes.
Responsiveness to caffeine
Because the SR is the common denominator of all three positive ino-
tropic interventions, we tested its functionality using a brief applica-
tion of caffeine (10 mM) which opens RyR2 channels and releases
SR Ca2+. In agreement with our previous report [5], in control car-
diomyocytes, caffeine caused an abrupt increase in [Ca2+]i concomi-
tant with contraction cessation, followed by a gradual decline in
[Ca2+]i along with resumption (within ~13 sec.) of contractions
(Fig. 5A). In contrast, in SCO2E140K cardiomyocytes (Fig. 5B and C),
the response to caffeine was different, and included two major types,
with equal proportions. In 45% of the experiments (total of 22), the
response (termed ‘fast recovery’, FR) was smaller and shorter than
control, and contractions resumed within ~0.8–5 sec. after caffeine
application (Fig. 5B and F). In 45% of cardiomyocytes, the response
amplitude was similar to control but recovery was much slower,
within 21–89 sec. (Fig. 5C and F); this group was termed ‘slow
recovery’ (SR). The remaining 10% of the SCO2E140K mutated iPSC-
CMs displayed a healthy-like behaviour. Similarly (Fig. 5D and E),
31% of the SCO2G193S cardiomyocytes (total of 13) had FR, 54% SR
and 15% control-like response. To quantify the response to caffeine,
we calculated three parameters: (i) recovery time—the time from the
peak of caffeine-induced [Ca2+]i rise to the first transient; (ii) the per
cent change in caffeine-induced [Ca2+]i signal amplitude, compared to
pre-caffeine amplitude; and (iii) the per cent change in caffeine-
induced Ca2+ signal area, compared to the pre-caffeine value. In the
SR group of both SCO2-mutated cardiomyocytes, the recovery time
was longer (P < 0.05), and the area and amplitude were similar to
control cells (Fig. 5F–H). In the FR group, the SCO2G193 cells showed
similar recovery time to control, whereas SCO2E140K displayed shorter
recovery time (P < 0.05; Fig. 5F). In both mutations, the area and
amplitude were smaller than control (P < 0.05; Fig. 5G–H). In sum-
mary, the depressed SR Ca2+ release capacity of the SCO2-mutated
iPSC-CMs is likely to underlie the attenuated positive inotropic
responsiveness to increased isoproterenol, [Ca2+]o and AT-II.
Arrhythmias in the SCO2-mutated
cardiomyocytes
Transmembrane action potentials
The results obtained thus far suggest that in the mutated cardiomy-
ocytes, the SR is at least partially depleted of Ca2+, implying that the
cytoplasm is Ca2+ overloaded, which can thus give rise to delayed
afterdepolarizations (DADs) and triggered arrhythmias [10]. To
Fig. 4 The effects of increased [Ca2+]o on the [Ca
2+]i transients and contractions. (A) Ramp; (B) +d[Ca
2+]/dt; (C) d[Ca2+]/dt; (D) Lamp; (E) +dL/dt;
(F) dL/dt. The effect of [Ca2+]o on contraction characteristics of SCO2G193S (n = 6), SCO2E140K (n = 7) and control (n = 12) was expressed as per
cent change. The effects of AT-II on the [Ca2+]i transients and contractions. (G) Ramp; (H) +d[Ca
2+]/dt; (I) -d[Ca2+]/dt; (J) Lamp; (K) +dL/dt; (L) dL/
dt. The effect of AT-II on contraction characteristics of SCO2G193S (n = 7), SCO2E140K (n = 8) and control (n = 10) was expressed as percent
change. The effect on the [Ca2+]i transients was expressed as the percent change in the fluorescence ratio, F340/F380 (n = 6, n = 6 and n = 7, for
SCO2G193S, SCO2E140K and control respectively); Tyr: Tyrode’s solution; *P < 0.05, **P < 0.001 (versus control).
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determine whether the mutated cardiomyocytes exhibit arrhythmias
typical of Ca2+ overload, transmembrane action potentials were
recorded from small clusters of cardiomyocytes in the absence and
presence of increasing isoproterenol concentrations. As depicted in
Figure 6A, in control cardiomyocytes, isoproterenol caused a typical
dose-dependent positive chronotropic effect. In contrast (in agree-
ment with the Ca2+ overload concept), in SCO2E140K and SCO2G193S
cardiomyocytes (Fig. 6B and C), DADs began to appear under base-
line conditions (two of three experiments) or in the presence of low
(108 M) (2/3) isoproterenol concentration, respectively. In addition
to DADs, in mutated cardiomyocytes, increasing isoproterenol con-
centrations led to decreased firing rate (from 108 M) and oscilla-
tory pre-potentials (starting from 108 M and 107 M in SCO2G193S
and SCO2E140K cardiomyocytes, respectively) (4/6). Interestingly, in
one of the experiments with SCO2E140K cardiomyocytes, 109 M
isoproterenol markedly increased the firing rate and eliminated the
DADs, but then starting from 108 M prominent DADs appeared
along with a decline in the firing rate (Fig. 6C).
Extracellular electrograms recorded from contracting
cardiomyocyte networks
To support the arrhythmogenic findings at the single cell level, we con-
firmed the presence of isoproterenol-induced arrhythmias in a network
of contracting cardiomyocytes, by recording extracellular electrograms
using the MEA system, in the absence and presence of isoproterenol.
In the absence of isoproterenol, the spontaneous beat rate was similar
in the three experimental groups (Fig. 7A), suggesting the basic pace-
maker machinery was not affected by the SCO2 mutations. In agree-
ment with the reduced inotropic and chronotropic responsiveness to
isoproterenol (Figs. 3 and 6), the mutated cardiomyocytes from both
patients exhibited an attenuated positive chronotropic response
(Fig. 7B) compared to control cardiomyocytes. In these experiments,
the cells were initially perfused for 30 min. with serum-free DMEM
solution at 37°C, followed by 10 min. of perfusion with increasing con-
centrations of isoproterenol (109 M–106M). Concomitant with the
smaller chronotropic response, isoproterenol (106M) caused arrhyth-
mias expressed by the irregular spontaneous firing rate (Fig. 7C–E),
compatible with the arrhythmia at the single cell level. As expected,
these arrhythmias were blocked by metoprolol. These findings were
repeated in 9 control and 15 mutated cardiomyocytes.
BRV characteristic in SCO2-mutated versus control
cardiomyocytes
As we previously demonstrated that disturbed intracellular Ca2+ han-
dling (likely to occur in the SCO2-mutated cardiomyocytes) augments
the BRV indices [11, 12], we compared the BRV characteristic in
mutated versus control cardiomyocytes. To this end, spontaneous
electrograms were recorded for 30 min., and BRV analysis performed
in the three experimental groups. The first indication of increased
BRV in the mutated cardiomyocytes is demonstrated by the dissimilar
Fig. 5 The effects of caffeine on control, SCO2 E140K and SCO2G193S iPSC-CMs. [Ca2+]i transients from (A) control (B–C) SCO2
E140K and (D–E)
SCO2G193S iPSC-CMs, demonstrating the effect of caffeine. (F) The mean recovery time, calculated as the time from the peak of caffeine-induced
[Ca2+]i rise to the first measurable [Ca
2+]i transient; (G) per cent change in area of the caffeine-induced Ca
2+ signal compared to the pre-caffeine
area; (H) per cent change in caffeine-induced Ca2+ signal amplitude compared to the pre-caffeine amplitude. Control iPSC-CMs (n = 7), SCO2G193S
iPSC-CMs (n = 11), SCO2E140K iPSC-CMs (n = 20), *P < 0.05. Asterisk above bars connecting columns represents significant difference between
groups. Each SCO2-mutated group was divided into subgroups FR and SR according to type of reaction.
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inter-beat intervals (IBIs), compared to the fixed intervals in the con-
trol cells (Fig. 8A). The increased BRV in the mutated cardiomyocytes
is further illustrated by the IBI versus time plots (Fig. 8B, E and H),
and the histograms (Fig. 8C, F and I) depicting the number of events
at different interval ranges. As shown by the histograms, the range of
IBIs was broader in SCO2 mutated than in control cardiomyocytes.
Specifically, while in control cells, the IBIs range was ~300 msec, the
ranges in the SCO2G193S and the SCO2E140K were ~2000 msec. and in
2000–3000 msec., respectively. Accordingly, the IBIs coefficient of
variation (CV) values were larger (P < 0.05) in the mutated than in
control cardiomyocytes (Fig. 8M).
The BRV magnitude was further analysed by generating Poincare
plots and calculating SD1 and SD2 representing the standard devia-
tion (S.D.) of short-term and long-term IBI variability, respectively. In
support of the higher CV values, the representative (Fig. 8D, G and J)
and superimposed Poincare plots (Fig. 8K) illustrate the much larger
dispersion of the data points in the mutated cardiomyocytes. Accord-
ingly, except for the mean IBI that showed no significant difference
between control and mutated clones (Fig. 8L) and for SD1 which was
not different between control and SCO2G193S iPSC-CMs, the Poincare
plot indices were higher in the mutated (from both patients) than in
the control cardiomyoctes (Fig. 8M–O).
Discussion
Mutations in the SCO2 gene are among the most common causes of
COX deficiency [18] leading to HCM, heart and respiratory failure, and
Fig. 6 Transmembrane action potential recordings from control, SCO2G193S and SCO2E140K iPSC-CMs in response to increasing concentrations of
isoproterenol. (A) Representative recordings from control iPSC-CMs in the presence of Tyrode’s solution and isoproterenol concentrations of
109 M, 108 M, 107 M and 106 M. Control iPSC-CMs displayed a positive chronotropic response to increasing concentrations of isoproterenol,
represented by firing rate. (B) Recordings from SCO2G193S and (C) from SCO2E140K iPSC-CMs in the presence of Tyrode’s solution and increasing
isoproterenol concentrations. SCO2G193S iPSC-CMs show generation of DADs with isoproterenol. SCO2E140K iPSC-CMs display DADs under baseline
conditions and in the presence of different isoproterenol concentrations.
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death at infancy [19]. To investigate the mechanisms underlying the
pathological features of the affected cardiomyocytes, we tested the
hypothesis that the SCO2 mutation is associated with mitochondrial
abnormalities, and intracellular Ca2+-overload resulting in functional
derangements and arrhythmias. The major findings in SCO2 cardiomy-
ocytes were as follows: (i) ultrastructural abnormalities, mainly enlarged
mitochondria and distorted cristae; (ii) attenuated inotropic response to
b-adrenergic stimulation, [Ca2+]o and AT-II; (iii) abnormal responses to
caffeine administration; and (iv) DADs and triggered arrhythmias.
Ultrastructural abnormalities in SCO2-mutated
cardiomyocytes
Comprehensive TEM analysis in SCO2G193S cardiomyocytes demon-
strated age-dependent (15-, 30- and 45-day-old cultures) abnormali-
ties including enlargement of mitochondria, disorganized
mitochondrial cristae, intra-mitochondrial vacuoles, glycogen depos-
its and lipid droplets. In contrast, SCO2E140K cardiomyocytes had nor-
mal mitochondrial distribution and structure, but large cellular
glycogen deposits and lipid droplets. Currently, there is no explana-
tion for these differences; other than that mitochondrial abnormalities
seen in mitochondrial diseases are generally heterogeneous and there
is often no clear genotype–phenotype correlation. Hence, the muta-
tions in SCO2 are in different domains of the protein; the E140K
mutation is close to the copper binding site, while the G193S muta-
tion is in a different segment of the protein, which may also result in
different effects of the mutations.
Mitochondrial structural abnormalities, including massive prolifer-
ation, are a secondary effect of the complex IV deficiency, and there
is no universal explanation for how these structural changes come
about. Possibly, ATP shortage due to COX deficiency in the oxidative
phosphorylation pathway leads to a compensatory response causing
swelling of mitochondria in an effort to produce more ATP. Further,
mitochondrial proliferation is often (but certainly not always) seen in
mitochondrial diseases, and it is thought to be a compensatory mech-
anism involving PGC1 alpha/AMPK signalling [20]. Glycogen deposits
are typical in SCO2-mutated human cells [21]. Notably, the TEM find-
ings in cardiomyocytes are in agreement with the pathological find-
ings demonstrated in the muscle biopsies taken from the hospitalized
patients who showed mitochondrial abnormalities and low COX activ-
ity. This similarity further strengthens the validity of our model as an
in vitro recapitulation of the in vivo disease.
Attenuated response of SCO2-mutated iPSC-CMs
to positive inotropic interventions
In agreement with our previous studies and others [5, 17, 22]
in control iPSC-CMs, b-adrenergic stimulation, increased [Ca2+]o
Fig. 7 The chronotropic response of extracellular electrograms recorded from control, SCO2E140K and SCO2G193S iPSC-CMs to isoproterenol. (A) The
spontaneous beating rate of control (n = 11), SCO2E140K (n = 7) and SCO2G193S (n = 10) iPSC-CMs. (B) The effect of isoproterenol on the beat rate
of iPSC-CMs and the blocking effect of the b-blocker metoprolol. (C–E) The EB was perfused initially with DMEM solution (Control) and then with
isoproterenol 106 M in DMEM solution. The different time intervals denote the arrhythmia in the isoproterenol-treated SCO2-mutated EBs. The
arrhythmia was blocked by the b-blocker metoprolol. (C) Control, (D) SCO2E140K and (E) SCO2G193S iPSC-CMs. Results are expressed as per cent
change from control (absence of isoproterenol). The arrhythmia is marked by red bar; bpm: beats per minute; C: control conditions—DMEM solu-
tion in the absence of isoproterenol; Iso: Isoproterenol; Met: Metoprolol; *P < 0.05, **P < 0.001 (versus control).
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and AT-II caused prominent positive inotropic and lusitropic
effects (Fig. 3 and 4). In marked contrast to the control
responses, the mutated cardiomyocytes from both patients were
completely unresponsive to all three positive inotropic interven-
tions. As will be discussed below, the most probable explanation
for these findings is that a downstream common step in these
different inotropic cascades is impaired in SCO2-mutated car-
diomyocytes. In brief, higher [Ca2+]o augments the Ca
2+ chemi-
cal gradient, leading to increased ICa,L amplitude, resulting in
enhanced SR Ca2+ release which increases the contractile force.
Isoproterenol activates the b-adrenergic cascade which via
increased protein kinase A (PKA) activation, augments ICa,L
which enhances SR Ca2+ release, thereby augmenting contrac-
tion [15]. On the other hand, AT-II induces a positive inotropic
effect by binding to its respective membrane receptor, and acti-
vating phospholipase C (PLC) [17], which synthesizes 1,4,5-IP3,
in turn increasing intracellular Ca2+ by opening SR 1,4,5-IP3-
dependent Ca2+ channels. Collectively, the common denominator
of these three positive inotropic interventions is increased SR
Ca2+ release.
The mechanism underlying the attenuated
positive inotropic responsiveness
To test the hypothesis that impaired SR Ca2+ content/release is
responsible for the attenuated inotropic responses, we tested the
effect (in control and SCO2-mutated cardiomyocytes) of caffeine
which releases Ca2+ from the SR by reducing the activation
threshold of RyR2 [23]. Indeed, as illustrated in control cardiomy-
ocytes, in agreement with our previous study [5] caffeine induced
a long-lasting rise in [Ca2+]i along with a transient depression of
the contractions, followed by a gradual resumption of contrac-
tions. In contrast, the responses of mutated cardiomyocytes were
completely different, featuring two major phenomena. Both pheno-
types depicted a small and short (compared to control) Ca2+
spike: the first phenotype showed a FR and the second phenotype
depicted a SR of contractions. The residual 10–20% (depending
on the mutation) exhibited a control-like phenotype. Thus, while
control cardiomyocytes depicted a single typical response to caf-
feine, the mutated cells exhibited dissimilar (two types) responses
to caffeine. These two abnormal responses of the mutated
Fig. 8 The spontaneous electrical activity and BRV properties of control, SCO2E140K and SCO2G193S iPSC-CMs. (A) EBs were perfused with DMEM
solution, activation spikes and repolarization waves were recorded in control, SCO2E140K and SCO2G193S iPSC-CMs (first recorded at 75 sec. and
then at 456 sec.). Inter-beat intervals (IBIs), histograms and Poincare plots analysis in control (B–D), SCO2G193S (E–G) and SCO2E140K iPSC-
CMs (H–J). (B, E, H) IBIs time series, (C, F, I) Histogram distribution of IBIs, (D, G, J) Poincare plots of the BRV. (K) Combined Poincare plots
of (D, G, J). (L–O) Comparisons of BRV magnitude in control (n = 8), SCO2E140K (n = 5) and SCO2G193S (n = 8). (L) Summary of mean IBI,
(M) coefficient of variance of IBIs (IBI CV), (N) SD1 and (O) SD2 of Poincare plots in contracting EBs. Altered time intervals were marked by
red bar. *P < 0.05.
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cardiomyocytes were demonstrated previously in sarcomeric-HCM
mutated cardiomyocytes [24].
While currently we cannot offer an explanation for the SR and FR
phenotypes, it is likely they are both caused by disturbed intracellular
Ca2+ handling resulting from the SCO2 mutation and COX impairment.
Specifically, the most likely element underlying these Ca2+ handling
abnormalities is the ATP-dependent SERCA pump, responsible for Ca2+
re-uptake into the SR [25, 26], and thus ATP shortage is expected to
reduce its activity. Therefore, the depressed ATP synthesis and conse-
quently reduced SERCA activity results in lower SR Ca2+ stores, leading
to attenuated RyR2-mediated Ca2+-induced-Ca2+-release. Collectively,
whereas the three positive inotropic stimuli tested (b-adrenergic
stimulation, increased [Ca2+]o and AT-II) augment contraction via dif-
ferent pathways (Fig. 9), they share one common downstream ele-
ment, which is impaired in SCO2-mutated cardiomyocytes—ATP-
dependent SR Ca2+ storage capacity. Finally, an important observation
that needs to be reconciled with the attenuated positive inotropic
response is the control-like basal [Ca2+]i transient and contraction char-
acteristics in the SCO2-mutated cardiomyocytes (Fig. S5). These
results suggest that under unstressed conditions, the basal SR Ca2+
content maintained by the existing ATP levels (produced by a combina-
tion of glycolysis and oxidative phosphorylation) is sufficient to support
the excitation-contraction coupling machinery [26]. However, these
depressed SERCA-dependent Ca2+ levels are insufficient to provide the
Fig. 9 Schematic model of a proposed mechanism for the observed abnormalities in SCO2 iPSC-CMs. The scheme describes the three distinct cellular
pathways converging at the sarcoplasmic reticulum (SR). The scheme suggests an explanation for the delayed afterdepolarizations (DADs) and the
attenuated inotropic responsiveness of SCO2-mutated cardiomyocytes. While in control cardiomyocytes, these different pathways cause positive ino-
tropic and lusitropic effects due to SR Ca2+ release, in SCO2-mutated iPSC-CMs, Ca2+ depleted SR accounts for the impaired inotropic responses.
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excessive Ca2+ required to generate a positive inotropic effect. Finally,
our findings are consistent with previous studies demonstrating ATP
shortage as a cause of HCM [27–30]. Low ATP levels lead to abnor-
mally high levels of cytosolic Ca2+ due to impaired SERCA activity. The
high Ca2+ concentration activates various downstream proteins and
pathways including Ca2+/calmodulin-dependent protein phosphatase
(calcineurin), different nuclear factors of activated T cells (NFAT), Ca2+/
calmodulin-dependent protein kinase (CaMK) and p38 mitogen-acti-
vated protein kinase, which eventually results in HCM and cardiac dys-
function [31].
As depicted in Figure 9, we propose a unified theory underlying
the described abnormalities in SCO2 iPSC-CMs. The attenuated
response of the mutated cardiomyocytes to positive inotropic stimu-
lation (in the form of isoproterenol, AT-II and Ca2+ administration) all
indicate abnormalities in different cellular pathways converging at the
SR. Together with damaged mitochondria demonstrated by TEM anal-
ysis, we singled out SERCA, the ATP-dependent pump responsible for
Ca2+ re-uptake into the SR, as a suspected dysfunctional key element
resulting in intracellular Ca2+ overload. In agreement with this conclu-
sion, spontaneous action potential recordings demonstrated DADs,
known to originate from Ca2+ overload as well.
In summary, collectively, our novel findings reveal abnormal intra-
cellular Ca2+ handling in SCO2-mutated cardiomyocytes, accounted
for by ATP shortage due to the impaired mitochondrial respiratory
chain function. These findings are consistent with other HCM iPSC-
CMs studies which demonstrated irregular Ca2+ handling as a funda-
mental mechanism underlying the disease pathology [32]. However,
in this study, we present for the first time Ca2+ abnormalities as a
prominent aspect of mitochondrial-related HCM. Furthermore, the
similar properties of different HCM subtypes may indicate a basic
common mechanism to which pathological Ca2+ handling can be
attributed. Additional research is required to determine whether a
common mechanism is indeed responsible for the similar phenotypes
or perhaps the resembling outcomes originate from different causes
leading to the same HCM disease.
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